The AMDHD1 Knockout HAP1 Polyclonal Cells comprise a heterogeneous population of HAP1 cells engineered via CRISPR/Cas9 to disrupt the AMDHD1 gene. This polyclonal knockout product provides a loss-of-function model for studying histidine catabolism and related metabolic pathways. Unlike clonal isolates, the pooled format minimizes selection bias while maintaining robust representation of edited alleles, facilitating population-level metabolic analyses. The ablation of imidazolonepropionase activity enables investigation of intermediate accumulation and metabolic rewiring in a genetically streamlined context.
HAP1 is a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells. Its haploid karyotype permits efficient gene disruption with single-allele targeting, enabling clean loss-of-function phenotypes. HAP1 retains myeloid lineage characteristics and displays stable growth, making it an ideal platform for metabolic and functional genomics studies. The absence of a second allele eliminates confounding compensatory effects, thus enhancing the interpretability of knockout experiments.
AMDHD1 encodes imidazolonepropionase, which hydrolyzes 4-imidazolone-5-propanoate to N-formimino-L-glutamate in the histidine degradation pathway, acting downstream of HAL and UROC1. The enzyme serves as a metabolic bridge to FTCD, funneling carbon into the one-carbon pool and generating glutamate. AMDHD1 transcription is regulated by dietary histidine and the stress-responsive factor ATF4. Functional interaction with FTCD ensures efficient formimino group transfer, and loss of AMDHD1 disrupts histidine flux, one-carbon metabolism, and nitrogen homeostasis.
In HAP1 cells, AMDHD1 knockout recapitulates metabolic disruptions characteristic of histidine catabolism disorders, causing accumulation of 4-imidazolone-5-propanoate and upstream intermediates. This model mimics aspects of conditions like urocanic aciduria and facilitates investigation of crosstalk between histidine degradation and one-carbon metabolism. The haploid background ensures penetrant phenotypes, enabling clear dissection of AMDHD1 deficiency at the cellular level. These cells are valuable for uncovering modulators of histidine pathway flux and for exploring metabolic adaptations to blocked catabolism.
Applications include LC-MS-based metabolomic profiling of histidine pathway intermediates, imidazolonepropionase activity assays, and histidine challenge tests to evaluate metabolic robustness. Researchers confirm gene disruption using RT-qPCR and Western blotting, while FIGLU quantification monitors N-formimino-L-glutamate accumulation. The cells support functional genomics screens for synthetic lethal interactions and are ideal for validating AMDHD1 as a target in metabolic disease research. This product accelerates studies in amino acid biochemistry and drug discovery. For further information, please contact Ascent Research.
